Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | TPMT | P51580 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29599043 | 1.00 | LMNA (0.55) | LMNARAB9AMAPK1HTTALDH1A1 | |
| SCHEMBL28094523 | 0.86 | CYP1A2 (0.68) | LMNARAB9AMAPK1HTTALDH1A1 | |
| SCHEMBL313217 | 0.85 | LMNA (0.73) | LMNARAB9AMAPK1HTTALDH1A1 | |
| SCHEMBL30307554 | 0.85 | HTT (0.73) | LMNARAB9AMAPK1HTTALDH1A1 | |
| SCHEMBL156299 | 0.85 | HTT (0.73) | LMNARAB9AMAPK1HTTALDH1A1 | |
| SCHEMBL16957095 | 0.84 | RAB9A (0.47) | LMNARAB9AMAPK1HTTKMT2A | |
| SCHEMBL22973 | 0.83 | RAB9A (0.51) | LMNARAB9AMAPK1HTTKMT2A | |
| SCHEMBL157203 | 0.83 | MAPT (0.62) | LMNARAB9AMAPK1HTTALDH1A1 | |
| SCHEMBL3337646 | 0.83 | MAPK1 (0.58) | LMNARAB9AMAPK1HTTALDH1A1 | |
| SCHEMBL16866842 | 0.82 | HTT (0.51) | LMNARAB9AMAPK1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025149629-A1 | NOVEL CARBOXAMIDE COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2025-07-17 | — | — | WO | disclosed |
| WO-2024137968-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | CAPULUS THERAPEUTICS, LLC (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240209001-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | Chiesi Farmaceutici S.p. A. (IT) | 2024-06-27 | — | — | US | disclosed |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| EP-4261211-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2023-10-18 | — | — | EP | disclosed |
| CN-114835687-B | AhR inhibitors | 北京华森英诺生物科技有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-115093400-B | AhR inhibitor, application and preparation method thereof | 北京华森英诺生物科技有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-116348468-A | CFTR modulator compounds, compositions and uses thereof | 日东制药株式会社 | 2023-06-27 | — | — | CN | disclosed |
| CN-116262673-A | Preparation method of alpha-bromoacetophenone compound | 浙江工业大学 | 2023-06-16 | — | — | CN | disclosed |
| US-20230126280-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2023-04-27 | — | — | US | disclosed |
| EP-1487794-A1 | MONOCYCLIC AROYLPYRIDINONES AS ANTIINFLAMMATORY AGENTS | Bayer Aktiengesellschaft (DE) | 2004-12-22 | — | — | EP | disclosed |
| US-6756374-B2 | CYCLIN-DEPENDENT KINASE INHIBITORS SUCH AS (4-AMINO-2-((4-(4-METHYL-1-PIPERAZINYL)PHENYL)AMINO)-5-THIAZOLYL) (2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)METHANONE FOR TREATMENT OF BREAST, LUNG, COLON, AND PROSTATE CANCER/TUMORS | HOFFMANN-LA ROCHE INC. | 2004-06-29 | — | — | US | disclosed |
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20040087594-A1 | Diaminothiazoles having antiproliferative activity | DING QINGJIE (US) | 2004-05-06 | — | — | US | disclosed |
| US-20040082595-A1 | Intermediates useful in the preparation of diaminothiazoles | DING QINGJIE (US) | 2004-04-29 | — | — | US | disclosed |
| EP-1358169-A2 | DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-05 | — | — | EP | disclosed |
| WO-2003076405-A1 | MONOCYCLIC AROYLPYRIDINONES AS ANTIINFLAMMATORY AGENTS | BAYER HEALTHCARE AG (DE) | 2003-09-18 | — | — | WO | disclosed |
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2002-12-05 | — | — | US | disclosed |
| US-20020151554-A1 | Diaminothiazoles having antiproliferative activity | CHEN LI (US) | 2002-10-17 | — | — | US | disclosed |
| WO-2002057261-A2 | DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087594-A1 | Diaminothiazoles having antiproliferative activity | CDK4, CDK2, CDKL4 | LMNA 2122/4885RAB9A 4189/4885MAPK1 625/4885 |
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, FPR1, PTGES2 | LMNA 4037/4885RAB9A 3587/4885MAPK1 781/4885 |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | PDE4A, PDE4B, PDE5A | LMNA 4118/4885RAB9A 604/4885MAPK1 1902/4885 |
| US-20020151554-A1 | Diaminothiazoles having antiproliferative activity | CDK4, CDK2, CDKL4 | LMNA 2122/4885RAB9A 4189/4885MAPK1 625/4885 |
| US-20040082595-A1 | Intermediates useful in the preparation of diaminothiazoles | CDK4, CDK2, CDKL4 | LMNA 1526/4885RAB9A 3806/4885MAPK1 458/4885 |
| US-20240209001-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | TYK2, JAK3, JAK1 | LMNA 4155/4885RAB9A 3268/4885MAPK1 98/4885 |
| US-20040092552-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, PTGES2, FPR1 | LMNA 4107/4885RAB9A 3650/4885MAPK1 777/4885 |
| US-20230126280-A1 | HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS | DUT, TYMP, DPYD | LMNA 1856/4885RAB9A 3628/4885MAPK1 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.